| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/12/2013 | US8394930 Growth factor isoform |
| 03/12/2013 | US8394929 Nogo receptor-mediated blockade of axonal growth |
| 03/12/2013 | US8394925 Fc variants with altered binding to FcRn |
| 03/12/2013 | US8394924 Directed engagement of activating Fc receptors |
| 03/12/2013 | US8394771 Multimeric proteins and methods of making and using same |
| 03/12/2013 | US8394761 Methods for treating congestive heart failure |
| 03/12/2013 | US8394620 Two-component genome flavivirus and uses thereof |
| 03/12/2013 | US8394581 Test method on feline vaccinated with feline immunodeficiency virus vaccine, and antigen for use in the test |
| 03/12/2013 | US8394411 Papillomavirus pseudoviruses for detection and therapy of tumors |
| 03/12/2013 | US8394390 Neisserial antigenic peptides |
| 03/12/2013 | US8394389 Tuberculosis vaccine and method of using same |
| 03/12/2013 | US8394388 Mycobacterial mutants affecting host apoptosis |
| 03/12/2013 | US8394387 Recombinant modified Bacillus anthracis protective antigen for use in vaccines |
| 03/12/2013 | US8394386 Sequential oral, intranasal, or intramuscular administration of a replication-defective adenovirus comprising a first heterologous expression cassette, and an adeno-associated virus comprising a second heterologous expression cassette; side effect reduction in vaccine carriers |
| 03/12/2013 | US8394385 Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| 03/12/2013 | US8394384 Recombinant avian influenza vaccine and uses thereof |
| 03/12/2013 | US8394383 Allergens from Aspergillus versicolor, and method of detecting a mold allergy caused by interior rooms |
| 03/12/2013 | US8394382 Siglec-9 Binding Agents |
| 03/12/2013 | US8394381 Administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR); inhibiting angiogenesis |
| 03/12/2013 | US8394380 Compositions and methods for alzheimer's disease |
| 03/12/2013 | US8394379 Targeted cryptosporidium biocides |
| 03/12/2013 | US8394378 Antibodies binding human collagen II |
| 03/12/2013 | US8394377 Methods for treating cancer using combination therapy |
| 03/12/2013 | US8394376 Therapeutic agents for alzheimer's disease and cancer |
| 03/12/2013 | US8394375 Antibodies for amyloid specific peptides |
| 03/12/2013 | US8394374 Optimized antibodies that target HM1.24 |
| 03/12/2013 | US8394370 Nutritional formula for optimal gut barrier function |
| 03/12/2013 | US8394368 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 03/12/2013 | CA2676842C Methods of releasing sporocysts from oocysts using controlled shear forces |
| 03/12/2013 | CA2676185C Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis |
| 03/12/2013 | CA2550085C Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 03/12/2013 | CA2542332C Immunomodulating compositions and uses therefor |
| 03/12/2013 | CA2532726C Evaluation of adjuvanted vaccines |
| 03/12/2013 | CA2521174C Enhanced hiv-1 vaccines and methods for their use |
| 03/12/2013 | CA2506724C Antibodies, polypeptides and uses thereof |
| 03/12/2013 | CA2497744C Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3 |
| 03/12/2013 | CA2479927C Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| 03/12/2013 | CA2468888C Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 03/12/2013 | CA2461714C Treatment of chronic joint inflammation |
| 03/12/2013 | CA2366787C Compositions and methods for treating lymphoma |
| 03/12/2013 | CA2295552C Cloned genomes of infectious hepatitis c viruses and uses thereof |
| 03/12/2013 | CA2285923C Methods and compositions for treating inflammatory bowel disease |
| 03/07/2013 | WO2013033734A1 Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
| 03/07/2013 | WO2013033563A1 Pegylated liposomes for delivery of immunogen-encoding rna |
| 03/07/2013 | WO2013033420A1 Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
| 03/07/2013 | WO2013033400A2 Methods for effectively and rapidly desensitizing allergic patients |
| 03/07/2013 | WO2013033398A1 Engineered sequences to facilitate expression of antigens in neisseria and methods of use |
| 03/07/2013 | WO2013033363A1 Mycobacterium tuberculosis porins and toxins and related methods |
| 03/07/2013 | WO2013033362A1 Yeast expression of flavivirus virus-like particles and use thereof |
| 03/07/2013 | WO2013033319A2 A cluster of neutralizing antibodies to hepatitis c virus |
| 03/07/2013 | WO2013033104A1 CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2) |
| 03/07/2013 | WO2013033092A2 Streptococcus suis pilus antigens |
| 03/07/2013 | WO2013033069A1 Human rhinovirus (hrv) antibodies |
| 03/07/2013 | WO2013032948A1 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 03/07/2013 | WO2013032943A1 Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition |
| 03/07/2013 | WO2013032942A1 Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| 03/07/2013 | WO2013032643A2 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 03/07/2013 | WO2013032404A1 Human enterovirus specific antibodies and their uses in diagnostics |
| 03/07/2013 | WO2013032028A1 New compound material, medicine containing same, and cancer treatment method using same |
| 03/07/2013 | WO2013031956A1 NUCLEIC ACID CONSTRUCT INCLUDING NUCLEIC ACID DERIVED FROM GENOTYPE 3a HCV GENOME |
| 03/07/2013 | WO2013031882A1 Vaccine preparation for cancer treatment |
| 03/07/2013 | WO2013031827A1 Rsv mucosal vaccine |
| 03/07/2013 | WO2013030783A1 Immunogenic proteins and compositions |
| 03/07/2013 | WO2013030670A2 Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers |
| 03/07/2013 | WO2013030608A1 Nanoparticle-based veterinary vaccine |
| 03/07/2013 | WO2013030604A1 Influenza virus antibody compositions |
| 03/07/2013 | WO2013030568A1 Caninised tumour necrosis factor antibodies and methods of using the same |
| 03/07/2013 | WO2013030378A1 Adjuvanted formulations of staphylococcus aureus antigens |
| 03/07/2013 | WO2013030320A1 Synthetic capsid proteins and uses thereof |
| 03/07/2013 | WO2013030176A2 Live attenuated influenza virus |
| 03/07/2013 | WO2013029570A1 Use of the pacap as a molecular adjuvant for vaccines |
| 03/07/2013 | WO2013010028A3 COMPOSITIONS AND METHODS FOR IMPROVED CaMKII INHIBITORS AND USES THEREOF |
| 03/07/2013 | WO2012169741A3 Fcεri-specific human antibody and composition comprising same for treating or diagnosing allergic diseases |
| 03/07/2013 | WO2012169735A3 Complex comprising water-soluble fragments of fcεri and composition comprising same for treating allergic diseases mediated by ige |
| 03/07/2013 | WO2012148538A3 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin |
| 03/07/2013 | WO2012062873A3 Highly immunogenic hiv p24 sequences |
| 03/07/2013 | US20130059752 Compositions and methods for the treatment of immune related diseases |
| 03/07/2013 | US20130059337 Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin |
| 03/07/2013 | US20130059009 Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers |
| 03/07/2013 | US20130058997 Vaccine composition containing synthetic adjuvant |
| 03/07/2013 | US20130058982 Method of treating Alzheimer's disease |
| 03/07/2013 | US20130058981 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 03/07/2013 | US20130058979 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| 03/07/2013 | US20130058978 Induced tolerogenic dendritic cells for inducing regulatory b cells |
| 03/07/2013 | US20130058977 Compositions and methods related to induced tolerogenic dendritic cells externally loaded with mhc class i-restricted epitopes |
| 03/07/2013 | US20130058975 Antigen-specific induced tolerogenic dendritic cells to reduce antibody responses |
| 03/07/2013 | US20130058974 Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
| 03/07/2013 | US20130058973 Immune therapy |
| 03/07/2013 | US20130058972 Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| 03/07/2013 | US20130058971 Innoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides |
| 03/07/2013 | US20130058970 Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
| 03/07/2013 | US20130058969 Chloroplasts engineered to express pharmaceutical proteins |
| 03/07/2013 | US20130058968 Piscine reovirus immunogenic compositions |
| 03/07/2013 | US20130058967 Recombinant modified bacillus anthracis protective antigen for use in vaccines |
| 03/07/2013 | US20130058966 Anti-pdef antibodies and uses thereof |
| 03/07/2013 | US20130058965 Injectable formulations for parenteral administration |
| 03/07/2013 | US20130058964 Methods for activating t cells and modulating an immune response |
| 03/07/2013 | US20130058963 Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells |
| 03/07/2013 | US20130058962 Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| 03/07/2013 | US20130058961 Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition |